Mutations galore in myeloproliferative neoplasms: Would the real Spartacus please stand up? (Q54574818)

1 June 2018

editorial

0 references

title

Mutations galore in myeloproliferative neoplasms: would the real Spartacus please stand up? (English)

1 reference

1 June 2018

Mutations galore in myeloproliferative neoplasms: Would the real Spartacus please stand up? (English)

1 reference

6 December 2024

1

A Tefferi

1 reference

1 June 2018

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21750560

6 December 2024

publication date

1 July 2011

1 reference

1 June 2018

July 2011

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21750560

full work available at URL

6 December 2024

https://www.nature.com/articles/leu201192.pdf

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21750560

https://www.nature.com/articles/leu201192.pdf

6 December 2024

file format

Portable Document Format

1 reference

https://www.nature.com/articles/leu201192

6 December 2024

1 reference

6 December 2024

1 reference

1 June 2018

volume

25

1 reference

1 June 2018

issue

7

1 reference

1 June 2018

page(s)

1059-1063

1 reference

1 June 2018

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

cites work

1 reference

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

21 January 2018

1 reference

DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development

21 January 2018

1 reference

Rethinking how DNA methylation patterns are maintained

21 January 2018

1 reference

The DNMT3B DNA methyltransferase gene is mutated in the ICF immunodeficiency syndrome

21 January 2018

1 reference

Array-based genomic resequencing of human leukemia

21 January 2018

1 reference

DNMT3A Mutations in Acute Myeloid Leukemia

21 January 2018

1 reference

DNMT3a mutations in high-risk myelodysplastic syndrome parallel those found in acute myeloid leukemia

21 January 2018

1 reference

Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms

21 January 2018

1 reference

Genetic complexity of myeloproliferative neoplasms.

21 January 2018

1 reference

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation

21 January 2018

1 reference

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

21 January 2018

1 reference

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

21 January 2018

1 reference

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

21 January 2018

1 reference

Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms.

21 January 2018

1 reference

Lnk constrains myeloproliferative diseases in mice

21 January 2018

1 reference

Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera.

21 January 2018

1 reference

Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal

21 January 2018

1 reference

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

21 January 2018

1 reference

LNK mutation studies in blast-phase myeloproliferative neoplasms, and in chronic-phase disease with TET2, IDH, JAK2 or MPL mutations

21 January 2018

1 reference

JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations

21 January 2018

1 reference

IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis.

21 January 2018

1 reference

Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms

21 January 2018

1 reference

Induction of Tumors in Mice by Genomic Hypomethylation

21 January 2018

1 reference

Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2

21 January 2018

1 reference

Deregulation of H3K27 methylation in cancer

21 January 2018

1 reference

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

21 January 2018

1 reference

Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation

21 January 2018

1 reference

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

Preferential nuclear accumulation of JAK2V617F in CD34 but not in granulocytic, megakaryocytic, or erythroid cells of patients with Philadelphia-negative myeloproliferative neoplasia

21 January 2018

1 reference

JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin

21 January 2018

1 reference

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

21 January 2018

1 reference

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis

21 January 2018

1 reference

LNK mutations in JAK2 mutation-negative erythrocytosis.

21 January 2018

1 reference

Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F

21 January 2018

1 reference

Mutation in TET2 in myeloid cancers

21 January 2018

1 reference

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

21 January 2018

1 reference

Acquired mutations in TET2 are common in myelodysplastic syndromes

21 January 2018

1 reference

Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates

21 January 2018

1 reference

Mutations of JAK2 and TET2, but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis

21 January 2018

1 reference

Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1

21 January 2018

1 reference

Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia.

21 January 2018

1 reference

Mutations of ASXL1 gene in myeloproliferative neoplasms.

21 January 2018

1 reference

Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia

21 January 2018

1 reference

ASXL1 represses retinoic acid receptor-mediated transcription through associating with HP1 and LSD1

21 January 2018

1 reference

Additional sex comb-like 1 (ASXL1), in cooperation with SRC-1, acts as a ligand-dependent coactivator for retinoic acid receptor

21 January 2018

1 reference

Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes

21 January 2018

1 reference

Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms

21 January 2018

1 reference

Gain-of-function of mutated C-CBL tumour suppressor in myeloid neoplasms

21 January 2018

1 reference

Deletions of the transcription factor Ikaros in myeloproliferative neoplasms.

21 January 2018

1 reference

Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function

21 January 2018

1 reference

Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1

21 January 2018

1 reference

DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms

21 January 2018

1 reference

7 January 2021

DNMT3A mutations in myeloproliferative neoplasms

1 reference

7 January 2021

Recurrent DNMT3A mutations in patients with myelodysplastic syndromes

1 reference

7 January 2021

Immunodeficiency, centromeric heterochromatin instability of chromosomes 1, 9, and 16, and facial anomalies: the ICF syndrome

1 reference

7 January 2021

Clonal hierarchy and allelic mutation segregation in a myelofibrosis patient with two distinct LNK mutations

1 reference

7 January 2021

Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations

1 reference

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.92

1 reference

1 June 2018

1 reference

1 June 2018